8-K: Xencor to Restate Prior Financial Statements Due to Accounting Errors

Xencor, Inc. announced it will restate its financial statements from 2023 and 2024 due to errors related to a royalty transaction and tax treatment of research and development expenses.

Summary

• Xencor's Audit Committee has determined that prior financial statements from 2023 and 2024 should no longer be relied upon due to accounting errors.
• The errors relate to the accounting treatment of a royalty transaction with OMERS Life Sciences and the treatment of research and development expenses under Section 174 of the Internal Revenue Code.
• The royalty transaction, initially accounted for as deferred income, should have been treated as debt.
• This resulted in an understatement of accounts receivable by $12.4 million, an overstatement of deferred income by $156.9 million, an understatement of debt by $168.5 million, and an understatement of shareholders' equity by $0.8 million for the year ended December 31, 2023.
• Revenue was understated by $6.3 million and interest expense was understated by $5.5 million for the year ended December 31, 2023.
• Cash flow from operating activities was overstated by $163.0 million, while cash flow from financing activities was understated by the same amount for the year ended December 31, 2023.
• The company also understated research and experimental expenses that should have been capitalized for tax purposes, leading to an uncertain tax position estimated at $5.6 million for the year ended December 31, 2023.
• State income tax expense was understated by approximately $2.2 million, net of the federal benefit, for the year ended December 31, 2023.
• These errors resulted in material weaknesses in the company's internal control over financial reporting.
• Xencor plans to restate the affected financial statements and file amendments to its prior filings.
• The company intends to file the amendments prior to the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• RSM US LLP has withdrawn its reports on Xencor's internal control over financial reporting and consolidated financial statements for the year ended December 31, 2023, as well as its completed interim reviews for the interim periods ended March 31, 2024, June 30, 2024 and September 30, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financial statements, the identification of material weaknesses in internal control, and the withdrawal of the auditor's reports. While the company states that the restatement is not anticipated to have a material impact on its future business or operations, the situation creates uncertainty and erodes investor confidence.

Positives

• The company is diligently pursuing completion of the restatements and intends to file the Amendments prior to the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The restatement of the Affected Financial Statements is not anticipated to have a material impact on the Company's future business or operations.
• The matters will have no impact on the Company's cash, cash equivalents and marketable debt securities as reported in the Prior Filings.

Negatives

• Prior financial statements from 2023 and 2024 should no longer be relied upon.
• The company had material weaknesses in its internal control over financial reporting related to the royalty transaction and tax treatment of research and development expenses.
• RSM US LLP has withdrawn its reports on Xencor's internal control over financial reporting and consolidated financial statements for the year ended December 31, 2023, as well as its completed interim reviews for the interim periods ended March 31, 2024, June 30, 2024 and September 30, 2024.

Risks

• There can be no assurance that the actual effects of the restatement will be only as described above.
• The company's internal review is ongoing and the company may identify further required changes to previously reported amounts or control findings.
• The company faces risks related to the timely and correct completion of the restatement and the Amendments.
• There is a risk that additional information may become known prior to the expected filing with the SEC of the periodic reports described herein or that other subsequent events may occur that would require the Company to make additional adjustments to its financial statements or delay the filing of the corrected or future periodic reports with the SEC.
• The company faces risks related to changes in the effects of the restatement on the Prior Filings or financial results.
• There are risks related to higher than expected charges after completing the restatement process.
• The company faces risks related to its ability to implement and maintain effective internal control over financial reporting in the future, which may adversely affect the accuracy and timeliness of its financial reporting.
• There are risks related to fluctuations in the company's tax obligations and effective tax rate and realization of its deferred tax assets, including net operating loss carryforwards, which may result in volatility of its results of operations.
• The company faces risks related to the timing and results of the company's review of the effectiveness of internal control over financial reporting and related disclosure controls and procedures.
• There are risks related to the application of accounting or tax principles in an unanticipated manner.
• The company faces risks related to its dependence on key personnel and any changes in its ability to retain key personnel.

Future Outlook

The company expects to complete the restatement and file the amendments to its prior filings before filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The restatement is not anticipated to have a material impact on the company's future business or operations.

Industry Context

Restatements due to accounting errors can erode investor confidence, particularly in the biotech industry where valuations are often based on future potential. Companies like Amgen, Gilead, and Regeneron are often compared to Xencor, and any financial uncertainty can negatively impact its standing relative to these peers.

Comparison to Industry Standards

• Restatements are not uncommon, but they raise concerns about internal controls.
• Companies like Teva Pharmaceutical Industries have faced similar issues with revenue recognition and required restatements.
• Xencor's situation will likely be compared to other biotech firms that have had to correct prior financial statements, such as Sage Therapeutics, to assess the severity and potential impact.
• The market will scrutinize Xencor's remediation plan and the timeliness of the restatement compared to industry benchmarks for resolving accounting issues.

Stakeholder Impact

• Shareholders may experience a decline in stock value due to the restatement and loss of confidence.
• Employees may be affected by the increased scrutiny and potential changes in internal controls.
• Creditors may reassess their risk exposure to the company.
• The company's reputation may be damaged, potentially affecting its relationships with partners and customers.

Next Steps

• The company will prepare amendments to each of the Prior Filings that include the restated financial statements.
• The company's remediation plans with respect to the material weaknesses described above will be included in the Amendments.
• The company intends to file the Amendments prior to the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Key Dates

Keywords

restatement, financial statements, accounting errors, internal control, material weakness, royalty transaction, research and development expenses, taxes, OMERS Life Sciences, Xencor